Nashville, TN — Westminster Pharmaceuticals has partnered with R&S Solutions as their preferred third-party logistics (3PL) provider to better serve pharmacies, hospitals, and patients nationwide. Westminster selected R&S Solutions to handle the fulfillment and distribution of all Westminster Pharmaceuticals products going forward due to their long-standing record as a leader in the pharmaceutical and related healthcare industry.
Mission Pharmacal enters into agreement with MainPointe Pharmaceuticals to purchase and license Mission’s consumer products
Houston and San Antonio, TX (January 3, 2018) – Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) of Houston, TX, and Mission Pharmacal Company (Mission) of San Antonio, TX, announced today that they have signed agreements providing for Mission to complete the technology transfer to develop and manufacture the registration batches of Fabre-Kramer’s novel antidepressant, Travivo (gepirone HCl) Extended Release Tablets. Data from these batches will be used to support the submission of the NDA Amendment for Travivo to the Food and Drug Administration (FDA) for review and approval. The two companies also expect to enter into an agreement for Mission to manufacture and package the commercial supplies of Travivo once approved.
SAN ANTONIO (October 24, 2017) – Ethics Follies® is a musical comedy which parodies popular Broadway shows and popular music. The original scripts are presented to licensed professionals and corporate executives as ethics training. The Association of Corporate Counsel (ACC), South/Central Texas Chapter, produces the original musical each year and was presented the “Outstanding Chapter Achievement Award for Innovative Programming” by the ACC in Washington, D.C. The award was announced at the ACC Annual Meeting Award Ceremony on Tuesday, October 17, 2017.
SAN ANTONIO (October 19, 2017)– BexR Logistix, LLC (“BexR”) is a full-service, U.S.-based, third-party Logistics Provider (3PL) and telesales organization that supplies a complete spectrum of a premiere, secure logistical support, and management services. Formed as the logistics and warehousing arm of parent company Mission Pharmacal Company (“Mission”), BexR’s roots lie squarely in pharmaceuticals. The sophistication and regulatory demands required to operate in that arena, however, have led clients from a wide variety of industries to discover the benefits of partnering with BexR.
Drug Store News recently spoke with Phillip Dritsas, SVP and general manager, consumer division and specialty markets for Mission Pharmacal, about the opportunities for Dr. Smith’s products in both the baby and adult categories.
SAN ANTONIO (August 1, 2017) – Mission Pharmacal Company (“Mission”) announced today that its President of Commercial Operations, Terry Herring, and Senior Vice President of Corporate Marketing, Natalie Sirjuesingh, were honored in the 2017 July/August issue of PharmaVOICE magazine for their contributions to the life sciences industry. Alamo Pharma Services (“Alamo”) Chief Operating Officer Peter Marchesini was also honored in the issue for his work with Alamo, a member of the Mission Family of Companies.
SAN ANTONIO (July 26, 2017) – For many years, San Antonio-based Mission Pharmacal Company (“Mission”) has manufactured and marketed highly specialized dermatology products. Utilizing only the finest ingredients, these products help ease patient suffering related to specific dermatologic conditions including acne, rosacea, seborrheic dermatitis, and other steroid responsive skin conditions. In 2016, the company acquired Glyderm® skin care products and formed Espada Dermatology, Inc. (“Espada”) to market the esthetic dermatology product line. A talented team of Mission dermatology experts and new leaders with their own extensive pharmaceutical experiences were brought together to lead Espada.The results have been so positive that Mission has shifted all products in its dermatology-related portfolio to Espada.
MIAMI, Fla. (April 25, 2017) – ProSolus, Inc. (“ProSolus”) is doubling down on its efforts to expand the utilization of transdermal drug delivery technologies. Today Mission Pharmacal Company (“Mission”) and ProSolus announced the expanded manufacturing capabilities of ProSolus and an increased emphasis on the company’s overall commercialization efforts. ProSolus, a wholly owned subsidiary of Mission, offers unrivaled expertise in the custom development and manufacturing of sophisticated and convenient transdermal and trans-mucosal drug delivery products to treat a variety of health conditions.
SAN ANTONIO (February 9, 2017) – Mission Pharmacal Company (“Mission”) celebrated the kick off of its 2017 fundraising campaign in support of the March of Dimes Foundation®, and its signature fundraiser March for Babies. The March of Dimes is committed to a world in which every baby gets a fighting chance. The company has been a national supporter of the March of Dimes since 2010 and during that time has contributed more than $2.1 million dollars to the organization through corporate sponsorship and fundraising efforts.